These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally. Hemmerling A; Potts M; Walsh J; Young-Holt B; Whaley K; Stefanski DA J Womens Health (Larchmt); 2007 Sep; 16(7):1041-51. PubMed ID: 17903081 [TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of lime juice as a topical microbicide candidate. Fletcher PS; Harman SJ; Boothe AR; Doncel GF; Shattock RJ Retrovirology; 2008 Jan; 5():3. PubMed ID: 18190686 [TBL] [Abstract][Full Text] [Related]
4. Use of lemon or lime juice douches in women in Jos, Nigeria. Imade GE; Sagay AS; Onwuliri VA; Egah DZ; Potts M; Short RV Sex Health; 2005; 2(4):237-9. PubMed ID: 16402671 [TBL] [Abstract][Full Text] [Related]
5. Genital tract abnormalities among female sex workers who douche with lemon/lime juice in Nigeria. Sagay AS; Imade GE; Onwuliri V; Egah DZ; Grigg MJ; Musa J; Thacher TD; Adisa JO; Potts M; Short RV Afr J Reprod Health; 2009 Mar; 13(1):37-45. PubMed ID: 20687264 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of HIV and other sexually transmissible infections in relation to lemon or lime juice douching among female sex workers in Jos, Nigeria. Imade G; Sagay A; Egah D; Onwuliri V; Grigg M; Egbodo C; Thacher T; Potts M; Short R Sex Health; 2008 Mar; 5(1):55-60. PubMed ID: 18361855 [TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the viability of vaginal cells (VK2/E6E7) and probiotic Lactobacillus species in lemon juice. Anukam KC; Reid G Sex Health; 2009 Mar; 6(1):67-74. PubMed ID: 19254495 [TBL] [Abstract][Full Text] [Related]
8. High Levels of Inflammatory Cytokines in the Reproductive Tract of Women with BV and Engaging in Intravaginal Douching: A Cross-Sectional Study of Participants in the Women Interagency HIV Study. Alcaide ML; Rodriguez VJ; Brown MR; Pallikkuth S; Arheart K; Martinez O; Roach M; Fichorova RN; Jones DL; Pahwa S; Fischl MA AIDS Res Hum Retroviruses; 2017 Apr; 33(4):309-317. PubMed ID: 27897054 [TBL] [Abstract][Full Text] [Related]
9. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433 [TBL] [Abstract][Full Text] [Related]
10. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents. Joanis CL; Hart CW AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522 [TBL] [Abstract][Full Text] [Related]
11. Intravaginal practices are associated with greater odds of high-risk HPV infection in Haitian women. Seay JS; Mandigo M; Kish J; Menard J; Marsh S; Kobetz E Ethn Health; 2017 Jun; 22(3):257-265. PubMed ID: 27774794 [TBL] [Abstract][Full Text] [Related]
12. Investigating widely available substances as vaginal microbicides. Holmes W Sex Health; 2004; 1(2):73-9. PubMed ID: 16334988 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. van De Wijgert J; Fullem A; Kelly C; Mehendale S; Rugpao S; Kumwenda N; Chirenje Z; Joshi S; Taha T; Padian N; Bollinger R; Nelson K J Acquir Immune Defic Syndr; 2001 Jan; 26(1):21-7. PubMed ID: 11176265 [TBL] [Abstract][Full Text] [Related]
14. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission. Yang J; Li L; Jin H; Tan S; Qiu J; Yang L; Ding Y; Jiang ZH; Jiang S; Liu S AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1498-508. PubMed ID: 22867271 [TBL] [Abstract][Full Text] [Related]
15. Randomized study of vaginal and neonatal cleansing with 1% chlorhexidine. Pereira L; Chipato T; Mashu A; Mushangwe V; Rusakaniko S; Bangdiwala SI; Chidede OS; Darmstadt GL; Gwanzura L; Kandawasvika G; Madzime S; Lumbiganon P; Tolosa JE Int J Gynaecol Obstet; 2011 Mar; 112(3):234-8. PubMed ID: 21247573 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Trottier S; Omar RF; Désormeaux A; Drouin J; Gagnon MT; Vezina F; Guilbert E; Mâsse B; Bergeron MG Contraception; 2007 Aug; 76(2):117-25. PubMed ID: 17656181 [TBL] [Abstract][Full Text] [Related]
17. Vaginal safety after use of a bioadhesive, acid-buffering, microbicidal contraceptive gel (ACIDFORM) and a 2% nonoxynol-9 product. Amaral E; Perdigao A; Souza MH; Mauck C; Waller D; Zaneveld L; Faundes A Contraception; 2006 May; 73(5):542-7. PubMed ID: 16627043 [TBL] [Abstract][Full Text] [Related]
18. A pilot study of the feasibility of a vaginal washing cessation intervention among Kenyan female sex workers. Masese L; McClelland RS; Gitau R; Wanje G; Shafi J; Kashonga F; Ndinya-Achola JO; Lester R; Richardson BA; Kurth A Sex Transm Infect; 2013 May; 89(3):217-22. PubMed ID: 23002190 [TBL] [Abstract][Full Text] [Related]
19. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan. Elias CJ; Coggins C; Alvarez F; Brache V; Fraser IS; Lacarra M; Lähteenmäki P; Massai R; Mishell DR; Phillips DM; Salvatierra AM Contraception; 1997 Dec; 56(6):387-9. PubMed ID: 9494773 [TBL] [Abstract][Full Text] [Related]
20. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]